Document:

Exhibit 10.11

 

AMENDMENT NO. 2 TO

EXCLUSIVE DISTRIBUTION AND LICENSING AGREEMENT 

BETWEEN 

WIZE PHARMA LTD. (FORMERLY STAR NIGHT TECHNOLOGIES LTD)

AND 

RESDEVCO LTD.

 

This
Amendment (the “Amendment”) refers to the Exclusive Distribution and Licensing Agreement between Wize Pharma
Ltd. ( the “Licensee”) and Resdevco Ltd. (the “Licensor”) signed on, May 1, 2015 as amended
on November 22, 2015 (the “Agreement”) and is entered into on the Execution Date (us defined below).

 

The
parties agree as follows:

 

		1.	The
                                         following shall he inserted at the end of Section 13.1 of the Agreement:

 

“Notwithstanding
the abovementioned, subject to a specific approval of the Licensor, Licensee may subordinate, pledge, secure or lien any of Licensee’s
rights arising from the Agreement, including but not limited, granting a floating charge or a fixed charge on Licensee’s rights,
to a Third Party whom the Licensor has approved in writing and in advance.

 

Licensee
and the Third Party shall be responsible ,separately and/or together, for the execution of the subordinated, pledged, secured
or lien part of the rights arising from the Agreenient pursuant to this Section 13.1.”

 

		2.	All
                                         other provisions of the Agreement that were not amended by this Amendment shall continue
                                         in full force and effect.

 

		3.	For
                                         the avoidance of doubt, in any event that the Licensee does not comply with any of the
                                         terms of the Agreement or violates any of the provisions of the Agreement, Licensor shall
                                         be entitled to cancel, abolish and void this Amendment and any rights to Licensee or
                                         Third Party arising from this Amendment shall be null and void accordingly.

 

		4.	Licensor
                                         hereby agrees for Licensee to grant all of the pledges on Licensee’s rights arising from
                                         the Agreement to Rimon Gold Nechasim Ltd. (corporate ID 514819424). For the avoidance
                                         of doubt, it is hereby clarified that all pledges or any other granted rights which arise
                                         from this Amendment shall be imposed only on the Licensee’s rights arising from the Agreement
                                         without derogating any of the Licensee’s obligations thereto, and shall in no way derogate
                                         from the Licensor’s rights arising from the Agreement, including, but not limited to,
                                         the provisions of termination of the Agreement. In this regard, all provisions of this
                                         Amendment shall be interpreted in the favour of the Licensor.

 

IN WITNESS WHEREOF, the parties hereto
have caused this Amendment to be executed by their duly authorised representatives on this 20 day of March, 2016 (the “Execution
Date”), with effect as of the Amendment Effective Date.

 

	Wize
    Pharma LTD.	 	 	 	 
	(formally Star Night Technologies Ltd)	 	Resdevco
    Ltd.	 
	 	 	 	 	 
	Signature:	/s/ Or Eisenberg

                                                                                
	 	Signature:	/s/ Prof. S. DiksteinExhibit 10.12

 

May
31, 2016

 

Amendment
1 to Licensing Agreement – Israeli Market

 

		1.	This
                                         Amendment refers to the Exclusive Distribution and Licensing Agreement between Resdevco
                                         Ltd. and Wize Pharma signed on May 1, 2015 (hereinafter called the “Agreement”)

 

		2.	Territory
                                         is extended to Israel, therefore the term Territory refers to both the USA and the Israeli
                                         markets.

 

		3.	If
                                         the Agreement is terminated for the USA Territory, this event will have no consequences
                                         on this Amendment with the original Agreement.

 

		4.	The
                                         term “FDA” should be replaced by “Ministry of Health in Israel” throughout
                                         the Agreement

 

		5.	The
                                         royalty payment per box/unit and guaranteed yearly minimum royalty payment commences
                                         on the date of signing this Amendment, overriding the date of section 7.1 of the Agreement

 

		6.	The
                                         following text overrides section 7.2 in the Agreement:

 

In
addition to the royalty per box/unit and guaranteed yearly minimum royalty payment LICENSEE will also pay RESDEVCO the following
amounts:

 

At
the time of commencing local sales an upfront nondeductible and nonrefundable payment of 30,000 US dollars (thirty thousand
US dollarS) is payable for the exclusive use of the Israeli Market License.

 

		7.	Based
                                         on the same calculations in section 7.3 of the Agreement, the following guaranteed minimum
                                         yearly royalty of plus the VAT according to the Israeli law, will be paid in January
                                         of each year.

 

At
the time of signature: $1200

 

2017:
$3000

2018:
$7200

2019:
$1800

2020
and following years: $ 36000

 

		8.	The
                                         following text overrides Section 12.3 of the Agreement:

 

Wize
Pharma may cancel this Agreement by informing Resdevco in writing 180 days in advance, but only following the commencement of
sales in Israel. In that case any previous payments made by WizePharma are non-refundable, any payment due during those 180 days
must be paid by Wize Pharma.

 

		9.	Presently
                                         the unit dose eye drops are registered in Israel as Eyecon®. WizePharma
                                         will inform Resdevco within 1 month whether it will be using the Eyecon®
                                         or Conheal® trademark in Israel, both of which are registered by Resdevco
                                         in Israel (see attachments below).

 

		10.	The
                                         definition of Product in the Agreement withstands regardless of the trademark selected
                                         by Wize Pharma

 

		11.	Within
                                         three months of signing of this Amendment, Wise Pharma will sign a Contract Manufacturing
                                         agreement (for a 30 unit box) with Pharmastulln. or with another manufacturer to supply
                                         the Product to the Israeli market.

  

    

     

    

 

		12.	Following
the signing of the contract manufacturing agreement, Wize Pharma will immediately:

 

		a.	Take
                                         over the job of Responsible Pharmacist from Ms. Rivka Slonim,

 

		b.	Continue
                                         the development of the product (translations of the PIL, box design etc.)

 

		c.	Begin
                                         the process of obtaining the claim of “Treating Conjunctivochalasis” in Israel,
                                         committing to obtaining such claim within three years of signing this Amendment. (Resdevco
                                         suggests to use the office of Ms. Rivka Slonim in Jerusalem, as she took care of past
                                         and present registrations of the unit dose eye drops).

 

		13.	In
Appendix A of the Agreement, sections 5 and 6 are not applicable.

 

		14.	Appendix
B of the Agreement is not applicable.

 

		15.	Appendix
C of the Agreement is not applicable as the documents related to the claim of “Treating Conjunctivochalasis” are already
in the possession of Dr. Gideon Stein through Nitsan Shmueli, advocate.

 

		16.	This
Amendment cancels any previous Amendment related to Israel

  

	/s/ Prof. S. Dikstein	 	/s/ Or Eisenberg
	Resdevco
Ltd	 	Wize Pharma LtdExhibit
10.13

 

Amendment
2 to Licensing Agreement – Ukraine Market

 

	1.	This
                                         Amendment refers to the Exclusive Distribution and Licensing Agreement between Resdevco
                                         Ltd. and Wize Pharma (formerly: Star Night Technologies) signed on May 1, 2015 (hereinafter
                                         called the “Agreement”)
	 	 
	2.	Territory
                                         is extended to The Ukraine, therefore the term Territory refers to both the USA and the
                                         Ukraine markets.
	 	 
	3.	If
                                         the Agreement is terminated for the USA Territory, this event will have no consequences
                                         on this Amendment with the original Agreement
	 	 
	4.	The
                                         term “FDA” should be replaced by “Ministry of Health of Ukraine”
                                         throughout the Agreement
	 	 
	5.	The
                                         royalty payment per box/unit and guaranteed yearly minimum royalty payment commences
                                         on the date of signing this Amendment, overriding the date of section 7.1 of the Agreement
	 	 
	6.	The
                                         following text overrides section 7.3 in the Agreement:

 

The
minimum guaranteed yearly royalty payment deductible from the total royalty per box/unit due will be paid to RESDEVCO in the same
calendar year and is not transferable to another year. Payment of the guaranteed yearly minimum royalty will be made to RESDEVCO
in January each year in one installment. VAT is added according to the law The minimum payments are as follows:

 

18,000
US dollars (eighteen thousand US dollars) in 2016 at the time of signature to this Amendment 2.

 

21,000
US dollars (twenty-one thousand US dollars) in January 2017.

 

30,000
US dollars (thirty thousand US dollars) in January 2018 and in all following years. Replacement of defected merchandise shall
not constitute necessity to pay royalty for the same actual sale.

 

	7.	Section
                                         12.3 of the Agreement is not applicable to this Amendment.
	 	 
	8.	Presently
                                         the unit dose eye drops are not registered in the Ukraine under any trademark. Registration
of Conheal® by Resdevco is already requested.

 

	9.	This
                                         Amendment will take effect at the time of signature and Resdevco will inform Pharmastulln
                                         immediately to allow Wise Pharma to sign a Contract Manufacturing regarding Ukraine.
	 	 
	10.	In
                                         Appendix A of the Agreement, sections 5 and 6 are not applicable
	 	 
	11.	Appendix
                                         B of the Agreement is not applicable
	 	 
	12.	Appendix
                                         C of the Agreement is not applicable as the documents related to the claim of “Treating
                                         Conjunctivochalasis” are already in the possession of Dr. Gideon Stein through
                                         Nitsan Shmueli, advocate.

 

	/s/ Prof. S. Dikstein	 	31.5.2016
	Resdevco Ltd	 	Date
	 	 	 
	/s/ Or Eisenberg	 	31/5/2016
	Wize Pharma Ltd	 	Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]